相关实验视频
Updated: Nov 27, 2025

07:44
Evaluation of Synapse Density in Hippocampal Rodent Brain Slices
Published on: October 6, 2017
17.7K
非正规的转化网络有助于阿尔茨海默病的突触损失
Tomohiro Nakamura1,2, Chang-Ki Oh3,2, Lujian Liao3
1Departments of Molecular Medicine and Neuroscience, and Neuroscience Translational Center, The Scripps Research Institute, La Jolla, CA 92037, USA. tnakamura@scripps.edu slipton@scripps.edu.
概括
不同的酶可以形成一个单独的转尼化网络,导致阿尔茨海默病 (AD) 的突触损失和认知衰退. 这种异常活动可能因其晚期出现而受到自然选择的影响较小.
科学领域:
- 生物化学
- 神经科学
- 酵素学
背景情况:
- 阿尔茨海默病 (AD) 的特征是突触损失和认知能力下降.
- 不同的酶通常以不同的生化途径运作.
- 异常的酶活性可能导致神经退行性疾病.
研究的目的:
- 识别导致阿尔茨海默病病理的新型酶功能.
- 研究跨化在突触损失中的作用.
- 在疾病中探索单独的酶网络的潜力.
主要方法:
- 基因酶,三酸酶和无素蛋白酸酶活动的表征.
- 在小鼠模型和人类AD样本中分析过化反应.
- 对转和突触损失之间的联系进行评估.
主要成果:
- 机械上不同的酶表现出非正规的转化功能.
- 这种转化级联与阿尔茨海默病病理有关.
- 异常的转基因化网络对阿尔茨海默病的突触损失有显著的贡献.
结论:
- 具有单独主要功能的酶可以形成异常转化的独特网络.
- 这种网络有助于阿尔茨海默病的认知衰退的主要病理相关性.
- 这种网络的晚期出现可能会减少对它的进化压力.
相关概念视频
Role of Neurotransmitters in Memory
2.1K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.1K
Alzheimer's Disease: Overview
1.2K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.2K
Neural Regulation
42.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.3K
Alzheimer's Disease: Treatment
596
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
596

